$Palatin Technologies (PTN.US)$
Palatin Technologies, Inc. announced positive Phase 3 trial results for PL9643, a potential treatment for dry eye disease (DED), presented by Dr. Eric Donnenfeld at the American Society of Cataract and Refractive Surgery Conference.
The study showed statistically significant improvement in pain and multiple seco...
Palatin Technologies, Inc. announced positive Phase 3 trial results for PL9643, a potential treatment for dry eye disease (DED), presented by Dr. Eric Donnenfeld at the American Society of Cataract and Refractive Surgery Conference.
The study showed statistically significant improvement in pain and multiple seco...
1